Hoth: FDA Accepts Pre-Investigational New Drug Submission for Treatment for Cancer

 

HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis https://www.biospace.com/article/releases/hoth-therapeutics-announces-fda-accepts-pre-investigational-new-drug-pre-ind-submission-for-ht-kit-treatment-for-cancer-patients/